< Zurück zu den aktuellen Neuigkeiten & Events

Auszeichnungen

HGF ranked Gold in the FT special report – Europe’s Leading Patent Law Firms 2022

Juni 2022

HGF has been ranked in the ‘Gold’ and ‘Silver’ bands in The Financial Times special report ‘Europe’s Leading Patent Law Firms’ published on the 16th June 2022.

More than 10,000 patent attorneys working in patent law firms or in the patent departments of companies, as well as clients, were directly invited to take part in the survey. Survey participants could recommend firms both in general and by specialities, categorised into six sectors. The sample was collected via research conducted by Statista on relevant company websites, in publications and from the EPI (the Institute of Professional Representatives Before the European Patent Office), the professional body representing European patent attorneys.

The firm is one of the leading firms of IP specialists in Europe, with 22 offices across the UK, Germany, The Netherlands, Switzerland, Austria, France and Ireland, and is internationally recognised by its peers across these core areas of technology.

HGF has been ranked in Gold “very frequently recommended” for:

  • Biotechnology & Food
  • Chemistry & Pharmaceuticals
  • Mechanical Engineering

Silver for “ frequently recommended” for:

  • Electrical Engineering
  • IT & Software
  • Materials & Nanotechnology

Dr Andrew Wells, Head of the Chemistry team commented,  “I’m delighted that our excellent reputation in the chemistry field has been recognised.  This is an excellent achievement for the HGF Chemistry team and for HGF as a whole. We have a large team of chemical patent attorneys located throughout Europe and we pride ourselves on providing commercially relevant and strategic IP advice to our clients.  We cover the whole chemistry landscape and have seen significant growth in the key areas of pharmaceuticals, formulation science, materials science, agrochemicals, process chemistry, fuel cells and electrochemistry. We also have a significant European oppositions practice that continues to go from strength to strength”.

Lucy Johnson, Head of the Engineering team commented, “We are delighted. Receiving a gold ranking recognition from our clients and peers is a reflection of the exceptional quality of the HGF Engineering team across Europe. The team has a wealth of technical and in-house expertise enabling us to provide strategic and relevant IP advice across the Engineering landscape.  Our work and reputation in the energy, automotive and healthcare sectors, in particular, is key to continuing to grow and develop our client partnerships”.

Kate Taylor, Head of the Life Sciences team commented, “Receiving this ranking is testament to the exceptional technical and legal knowledge of the HGF life sciences team in what is a continuingly evolving technology landscape. We have a depth of expertise across the sector, and of particular note is the work we have been undertaking in the area of CRISPR, Microbiome and biologic therapeutics”.

As one of Europe’s leading firms  firm we are committed to building strong client relationships and delivering outstanding service from our offices in Germany, The Netherlands, Switzerland, Austria, France, Ireland and the UK. We continue to deepen our understanding of the client experience and provide tailor made solutions for our clients in Europe and around the world. We are delighted to have been ranked in Gold and Silver, and believe it is our integrated approach providing multidisciplinary teams of patent attorneys, trade mark attorneys and IP solicitors; each guided by the great value we place on People, Teamwork, Excellence and Progressive.

For the full report see here

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen